A phase 1/2 trial of RC278 in advanced solid tumours, run by RemeGen Co., Ltd., now recruiting.
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors is a phase 1/2 interventional study registered as NCT07105215 by RemeGen Co., Ltd., with 312 participants planned, started 2025-08-11 and due to reach its primary completion in 2027-12-31. Interventions recorded: RC278.
Shares RemeGen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares RemeGen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.